Share on StockTwits

Evoke Pharma (NASDAQ:EVOK) announced its earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.14, Analyst Ratings News reports.

On the ratings front, analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Evoke Pharma in a research note on Tuesday, May 27th. They now have a $20.00 price target on the stock, up previously from $19.00. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $29.25.

Evoke Pharma (NASDAQ:EVOK) opened at 6.4599 on Thursday. Evoke Pharma has a 52-week low of $6.07 and a 52-week high of $14.25. The stock has a 50-day moving average of $7. and a 200-day moving average of $8.45. The company’s market cap is $39.4 million.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:EVOK), disorders and diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.